Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.
IMUNON advances Phase 3 with stronger survival data, signaling a shift in ovarian cancer immunotherapy
IMNN-001 shows improved survival in ovarian cancer. Find out what this means for Phase 3 success and future treatment strategies.
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
What AEON Biopharma Inc.’s analytical strategy reveals about the future of botulinum toxin biosimilars
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.
Can Sarepta Therapeutics prove RNA interference works in FSHD1 and DM1 with early Phase 1/2 data
Read why Sarepta Therapeutics’ first siRNA data in FSHD1 and DM1 could matter for rare disease drug development and investor sentiment.
Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground
FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Biocatalysis integration deal between SK pharmteco and Prozomix highlights greener pharma production shift
SK pharmteco partners with Prozomix to expand biocatalysis in drug manufacturing. Discover what this means for greener APIs and global CDMO strategy.
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.